Total debt surged 18-fold from $2.3M in 2026Q1 to $41.7M in 2026Q2, driving equity to -$3.2M against a -$152.2M retained earnings deficit, while cash fell 69% from $38.4M to $11.8M over the ten-quarter period.
EDAP TMS S.A. American Depositary Shares (FOCL) balance sheet — 29-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 |
|---|
| Total Current Assets | 94.78M | 57.16M | 72.36M | 86.69M | 96.61M | 76.63M | 55.54M | 47.25M | 46.16M | 47.52M | 42.72M | 33.04M | 26.55M | 22.17M | 24.73M | 27.05M | 29.86M | 33.25M | 35.79M | 36.18M | 26.39M | 22.76M | 22.02M | 25.83M | 34.12M | 46.01M | 39.99M | 23.97M | 33.34M | 40.45M |
| Cash & Short-Term Investments | 56.27M | 20.45M | 30.9M | 48.02M | 67.38M | 53.66M | 30.22M | 23.44M | 22.25M | 24.02M | 23.19M | 14.58M | 12.14M | 7.68M | 8.08M | 6.47M | 8.89M | 12.7M | 14.97M | 18.64M | 10.93M | 8.31M | 9.39M | 10.41M | 15.85M | 29.1M | 25.11M | 3.27M | 8.78M | 11.73M |
| Cash Only | 56.27M | 20.45M | 30.9M | 48.02M | 67.38M | 53.66M | 30.22M | 23.44M | 22.25M | 24.02M | 23.19M | 13.58M | 11.14M | 6.68M | 7.04M | 4.9M | 7.37M | 11.59M | 13.83M | 17.55M | 9.89M | 8.31M | 9.39M | 10.41M | 15.77M | 19.39M | 3.4M | 3.27M | 8.78M | 11.73M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1M | 1M | 1M | 1.04M | 1.57M | 1.52M | 1.11M | 1.14M | 1.09M | 1.03M | 0 | 0 | 0 | 81.95K | 9.7M | 21.71M | 0 | 0 | 0 |
| Accounts Receivable | 11.78M | 22.58M | 21.01M | 21.25M | 15.95M | 13.78M | 15.1M | 14.13M | 15.22M | 14.82M | 10.57M | 10.74M | 8.14M | 9.39M | 11.15M | 13.96M | 16.09M | 15.53M | 15.56M | 12.04M | 10.87M | 9.61M | 8.19M | 9.4M | 11.21M | 10.85M | 8.68M | 11.46M | 14.92M | 17.18M |
| Days Sales Outstanding | 94.15 | 116.51 | 110.56 | 118.74 | 100.5 | 96.58 | 116.02 | 102.59 | 120.21 | 134.16 | 97.98 | 121.59 | 110.95 | 142.37 | 156.11 | 228.51 | 247.73 | 227.71 | 246.39 | 196.58 | 195.85 | 168.71 | 134.96 | 186.11 | 204.72 | 165.02 | 115.93 | 218.3 | 234.83 | 191.63 |
| Inventory | 8.33M | 12.83M | 19.15M | 16.69M | 12.57M | 8.53M | 9.77M | 9.18M | 8.24M | 8.09M | 8.47M | 6.15M | 5.91M | 4.7M | 4.26M | 3.92M | 3.92M | 3.79M | 4.02M | 4.31M | 3.77M | 4.45M | 3.94M | 5.26M | 6.57M | 5.61M | 5.61M | 8.53M | 8.61M | 7.18M |
| Days Inventory Outstanding | 118.59 | 115.2 | 172.06 | 156.5 | 141.23 | 102.7 | 134.42 | 125.21 | 114.56 | 125.07 | 145.55 | 121.57 | 138.37 | 116.17 | 99.54 | 106.5 | 100.31 | 97.43 | 105.22 | 119.54 | 115.06 | 131.93 | 105.13 | 146.82 | 208.33 | 134.5 | 143.78 | 288.88 | 271.07 | 161.99 |
| Other Current Assets | 18.41M | 0 | 0 | 0 | 0 | 0 | 3 | 500.63K | 436.69K | 0 | 0 | 2.07M | 42K | 23K | 32K | 57K | 969K | 1.23M | 1.23M | 715.29K | 84.1K | 0 | 76.72K | 331.11K | 106.73K | 113.51K | 242.76K | 707.58K | 1.02M | 4.36M |
| Total Non-Current Assets | 15.93M | 21.83M | 16.76M | 14.44M | 11.32M | 11.19M | 11.99M | 12.31M | 9.56M | 8.79M | 6.42M | 5.54M | 5.54M | 4.75M | 5.72M | 5.5M | 6.07M | 7.13M | 8.08M | 8.89M | 6.08M | 6.01M | 5.86M | 6.03M | 5.7M | 7.2M | 10.43M | 12.49M | 12.02M | 10.45M |
| Property, Plant & Equipment | 10.41M | 13.5M | 10.7M | 9.05M | 6.39M | 5.88M | 6.85M | 7.54M | 4.81M | 4.42M | 2.92M | 2.12M | 2.12M | 1.66M | 2.04M | 2.53M | 2.88M | 3.29M | 3.76M | 4.19M | 3.21M | 3.13M | 2.8M | 2.9M | 1.99M | 2.24M | 1.83M | 3.1M | 1.71M | 2.82M |
| Fixed Asset Turnover | 5.51x | 5.24x | 6.48x | 7.22x | 9.07x | 8.86x | 6.93x | 6.67x | 9.61x | 9.12x | 13.48x | 15.19x | 12.62x | 14.55x | 12.81x | 8.80x | 8.24x | 7.57x | 6.13x | 5.34x | 6.31x | 6.65x | 7.90x | 6.36x | 10.06x | 10.73x | 14.93x | 6.19x | 13.60x | 11.61x |
| Goodwill | 732K | 2.83M | 2.5M | 2.66M | 2.57M | 2.74M | 2.95M | 2.71M | 2.76M | 2.9M | 2.54M | 2.41M | 2.41M | 2.41M | 2.41M | 2.41M | 2.41M | 2.41M | 2.41M | 2.42M | 2.41M | 2.41M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.82M | 1.8M | 1.12M | 1.2M | 772.69K | 827.88K | 931.12K | 864.33K | 968.25K | 632.82K | 157.16K | 39K | 24K | 37K | 72K | 68K | 82K | 103K | 102K | 78.88K | 71.22K | 86.12K | 2.53M | 2.58M | 2.64M | 2.52M | 2.73M | 5.09M | 5.71M | 6.45M |
| Long-Term Investments | 2.57M | 546K | 0 | 0 | 0 | 0 | 0 | 2.25K | 29.72K | 92.46K | 315.37K | 593K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2.7M | 2.06M | 1.57M | 719.13K | 700.12K | 720.99K | 801.43K | 717.28K | 625.3K | 552.37K | 471.47K | 969K | 982K | 647K | 1.2M | 484K | 702K | 1.33M | 1.8M | 2.21M | 386.42K | 390.07K | 522.28K | 547.09K | 1.07M | 2.44M | 5.88M | 4.31M | 4.6M | 1.18M |
| Total Assets | 110.72M | 79M | 89.12M | 101.13M | 107.92M | 87.82M | 67.53M | 59.57M | 55.72M | 56.31M | 49.14M | 38.58M | 32.15M | 26.87M | 30.44M | 32.55M | 35.94M | 40.38M | 43.86M | 45.07M | 32.47M | 28.77M | 27.88M | 31.85M | 39.82M | 53.21M | 50.43M | 36.46M | 45.36M | 50.91M |
| Asset Turnover | 0.75x | 0.90x | 0.78x | 0.65x | 0.54x | 0.59x | 0.70x | 0.84x | 0.83x | 0.72x | 0.80x | 0.84x | 0.83x | 0.90x | 0.86x | 0.68x | 0.66x | 0.62x | 0.53x | 0.50x | 0.62x | 0.72x | 0.79x | 0.58x | 0.50x | 0.45x | 0.54x | 0.53x | 0.51x | 0.64x |
| Asset Growth % | 24.02% | -11.36% | -11.88% | -6.3% | 22.89% | 30.05% | 13.37% | 6.91% | -1.06% | 14.59% | - | 19.99% | 19.65% | -11.73% | -6.47% | -9.43% | -11% | -7.95% | -2.69% | 38.8% | 12.86% | 3.2% | -12.47% | -20.01% | -25.16% | 5.51% | 38.3% | -19.62% | -10.9% | - |
| Total Current Liabilities | 36.07M | 37.14M | 39.15M | 30.48M | 23.17M | 20.41M | 26.31M | 19.64M | 19.22M | 19.37M | 15.83M | 16.27M | 12.16M | 11.59M | 13.12M | 20.7M | 14.66M | 15.18M | 14.46M | 12.9M | 10.93M | 9.87M | 8.27M | 10.99M | 9.82M | 11.94M | 10.21M | 13.99M | 13.56M | 13.36M |
| Accounts Payable | 0 | 11.78M | 13.06M | 12.41M | 7.09M | 6.27M | 6.98M | 6.79M | 7.2M | 7.58M | 6.29M | 6.1M | 5.5M | 5.43M | 5.82M | 5.72M | 4.31M | 4.06M | 5.07M | 5.07M | 3.99M | 3.53M | 2.91M | 3.15M | 4.2M | 5.45M | 4.42M | 4.9M | 3.33M | 5.09M |
| Days Payables Outstanding | 116.95 | 105.8 | 117.33 | 116.36 | 79.61 | 75.47 | 96.04 | 92.57 | 100.02 | 117.1 | 108.03 | 120.52 | 128.94 | 134.39 | 135.89 | 155.54 | 110.35 | 104.29 | 132.48 | 140.42 | 121.82 | 104.7 | 77.74 | 88 | 133.2 | 130.7 | 113.36 | 165.87 | 104.67 | 114.83 |
| Short-Term Debt | 12.69M | 9.35M | 10.17M | 5.71M | 4.89M | 4.27M | 10.18M | 5.98M | 5.21M | 4.03M | 2.18M | 3.02M | 2.24M | 2.3M | 2.3M | 9.02M | 3.94M | 4.52M | 2.81M | 2.25M | 2.6M | 2.2M | 1.63M | 1.21M | 1.85M | 1.8M | 2.48M | 2.45M | 3.58M | 454.55K |
| Deferred Revenue (Current) | 28.64M | 7.1M | 6.88M | 4.47M | 4.32M | 3.88M | 3.3M | 2.12M | 2.21M | 2.76M | 1.98M | 1.6M | 1.1M | 826K | 885K | 418K | 578K | 558K | 704K | 452.67K | 669.04K | 770.01K | 842.43K | 2.32M | 1.13M | 966.56K | 798.55K | 0 | 0 | 0 |
| Other Current Liabilities | 16.06M | 7.53M | 8.04M | 6.85M | 5.79M | 4.63M | 4.83M | 3.72M | 3.77M | 4.14M | 4.4M | 3.72M | 1.82M | 1.44M | 1.2M | 3.31M | 837K | 824K | 771K | 834.64K | 1.21M | 1.06M | 936.12K | 1.3M | 2.63M | 1.01M | 2.51M | 6.65M | 6.65M | 7.82M |
| Current Ratio | 2.63x | 1.54x | 1.85x | 2.84x | 4.17x | 3.75x | 2.11x | 2.41x | 2.40x | 2.45x | 2.70x | 2.03x | 2.18x | 1.91x | 1.88x | 1.31x | 2.04x | 2.19x | 2.48x | 2.80x | 2.42x | 2.31x | 2.66x | 2.35x | 3.48x | 3.85x | 3.92x | 1.71x | 2.46x | 3.03x |
| Quick Ratio | 2.40x | 1.19x | 1.36x | 2.30x | 3.63x | 3.34x | 1.74x | 1.94x | 1.97x | 2.04x | 2.16x | 1.65x | 1.70x | 1.51x | 1.56x | 1.12x | 1.77x | 1.94x | 2.20x | 2.47x | 2.07x | 1.86x | 2.19x | 1.87x | 2.81x | 3.38x | 3.37x | 1.10x | 1.82x | 2.49x |
| Cash Conversion Cycle | 95.8 | 125.91 | 165.29 | 158.88 | 162.12 | 123.81 | 154.4 | 135.23 | 134.75 | 142.13 | 135.5 | 122.63 | 120.39 | 124.14 | 119.76 | 179.47 | 237.69 | 220.86 | 219.14 | 175.71 | 189.09 | 195.94 | 162.35 | 244.94 | 279.86 | 168.82 | 146.35 | 341.32 | 401.23 | 238.79 |
| Total Non-Current Liabilities | 38.71M | 22.44M | 7.62M | 7.77M | 8.31M | 10.49M | 7.76M | 8.02M | 6.77M | 5.48M | 7.27M | 7.88M | 4.86M | 6M | 9.16M | 3.14M | 12.38M | 12.62M | 12.21M | 17.65M | 2.25M | 1.55M | 1.66M | 1.93M | 1.61M | 2.29M | 5.44M | 7M | 6.91M | 3.73M |
| Long-Term Debt | 615K | 15.9M | 2.24M | 2.21M | 3.83M | 5.61M | 1.4M | 1.07M | 1.53M | 1M | 405.02K | 592K | 342K | 239K | 4.83M | 720K | 8.79M | 9.33M | 9.05M | 11.69M | 58.34K | 54.88K | 0 | 7.15K | 95.3K | 304.58K | 3.16M | 6.36M | 5.54M | 1.55M |
| Capital Lease Obligations | 5.61M | 2.43M | 2.01M | 1.45M | 1.31M | 1.5M | 2.02M | 2.67M | 973.96K | 634.02K | 330.14K | 294K | 355K | 378K | 494K | 695K | 961K | 1.37M | 1.31M | 1.03M | 696.32K | 473.66K | 662.44K | 579.64K | 0 | 229.28K | 332.2K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.49M | 4.08M | 5.34M | 3.75M | 0 | 1.29M | 808K | 447K | 0 | 0 | 6.75K | 0 | 0 | 0 | 0 | 0 | 0 | 426.33K | 545.45K |
| Other Non-Current Liabilities | 38.09M | 3.14M | 3M | 3.4M | 2.89M | 2.88M | 3.21M | 2.8M | 3.16M | 3.17M | 6.18M | 505K | 75K | 48K | 2K | 1.47M | 1.05M | 784K | 822K | 4.21M | 1.49M | 1.01M | 1M | 1.35M | 1.51M | 1.76M | 1.95M | 636.03K | 937.93K | 1.64M |
| Total Liabilities | 74.78M | 59.58M | 46.77M | 38.25M | 31.47M | 30.9M | 34.07M | 27.66M | 25.99M | 24.86M | 23.1M | 24.15M | 17.01M | 17.59M | 22.28M | 23.84M | 27.04M | 27.8M | 26.67M | 30.55M | 13.17M | 11.42M | 9.93M | 12.93M | 11.42M | 14.23M | 15.65M | 20.99M | 20.46M | 17.09M |
| Total Debt | 13.3M | 27.68M | 14.41M | 9.37M | 10.02M | 11.38M | 13.6M | 9.72M | 7.71M | 5.67M | 2.91M | 4.15M | 3.16M | 3.1M | 8.09M | 12.96M | 14.38M | 16.06M | 13.88M | 14.92M | 3.35M | 2.73M | 2.29M | 1.8M | 1.95M | 2.33M | 5.97M | 8.81M | 9.12M | 2M |
| Net Debt | -42.97M | 7.23M | -16.48M | -38.65M | -57.36M | -42.28M | -16.62M | -13.72M | -14.54M | -18.36M | -20.28M | -9.43M | -7.99M | -3.58M | 1.04M | 8.06M | 7.01M | 4.47M | 58K | -2.63M | -6.54M | -5.58M | -7.1M | -8.61M | -13.82M | -17.06M | 2.57M | 5.54M | 341.06K | -9.73M |
| Debt / Equity | 0.37x | 1.43x | 0.34x | 0.15x | 0.13x | 0.20x | 0.42x | 0.32x | 0.27x | 0.19x | 0.11x | 0.29x | 0.21x | 0.33x | 0.99x | 1.49x | 1.62x | 1.28x | 0.81x | 1.03x | 0.17x | 0.16x | 0.13x | 0.09x | 0.07x | 0.06x | 0.17x | 0.57x | 0.37x | 0.06x |
| Debt / EBITDA | -0.46x | - | - | - | - | - | 6.62x | 2.65x | - | - | 1.86x | 2.78x | - | - | - | - | 2.85x | 3.21x | 2.14x | 2.77x | 0.77x | 1.08x | 1.22x | 0.20x | 0.33x | 0.37x | 1.17x | - | 1.19x | 3.14x |
| Net Debt / EBITDA | 1.50x | - | - | - | - | - | -8.09x | -3.74x | - | - | -12.95x | -6.33x | - | - | - | - | 1.39x | 0.89x | 0.01x | -0.49x | -1.50x | -2.21x | -3.78x | -0.95x | -2.34x | -2.74x | 0.51x | - | 0.04x | -15.29x |
| Interest Coverage | -3.96x | -35.98x | -80.30x | -89.28x | -14.93x | 6.31x | -3.77x | 7.25x | -18.02x | -46.07x | 6.86x | -11.88x | -5.09x | -1.48x | -2.56x | 0.38x | -4.51x | -4.29x | 2.17x | -13.74x | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 35.94M | 19.41M | 42.35M | 62.88M | 76.45M | 56.92M | 32.12M | 30.71M | 28.54M | 30.21M | 25.79M | 14.43M | 15.14M | 9.28M | 8.16M | 8.71M | 8.9M | 12.58M | 17.19M | 14.52M | 19.3M | 17.36M | 17.95M | 18.93M | 28.4M | 38.98M | 34.78M | 15.47M | 24.9M | 33.82M |
| Equity Growth % | -205.6% | -54.16% | -32.65% | -17.75% | 34.31% | 77.24% | 4.58% | 7.61% | -5.54% | 17.14% | - | -4.7% | 63.09% | 13.76% | -6.34% | -2.1% | -29.25% | -26.83% | 18.38% | -24.76% | 11.18% | -3.3% | -5.16% | -33.35% | -27.14% | 12.08% | 124.8% | -37.87% | -26.38% | - |
| Book Value per Share | 0.84 | 0.52 | 1.14 | 1.70 | 2.22 | 1.76 | 1.10 | 1.04 | 0.98 | 1.04 | 0.88 | 0.58 | 0.64 | 0.45 | 0.46 | 0.65 | 0.68 | 1.19 | 1.78 | 1.58 | 2.02 | 2.07 | 2.22 | 2.42 | 3.63 | 4.91 | 4.21 | 1.98 | 2.99 | 5.07 |
| Total Shareholders' Equity | 35.94M | 19.41M | 42.35M | 62.88M | 76.45M | 56.92M | 32.12M | 30.71M | 28.54M | 30.21M | 25.79M | 14.43M | 15.14M | 9.28M | 8.16M | 8.71M | 8.9M | 12.58M | 17.19M | 14.52M | 19.3M | 17.36M | 17.95M | 18.93M | 28.4M | 38.98M | 34.78M | 15.47M | 24.9M | 33.82M |
| Common Stock | 7.53M | 6.07M | 5.06M | 5.36M | 5.1M | 4.99M | 4.69M | 4.29M | 4.36M | 4.58M | 3.99M | 3.35M | 3.28M | 2.88M | 2.44M | 1.78M | 1.74M | 1.42M | 1.3M | 1.25M | 1.21M | 1.09M | 1.09M | 1.09M | 1.09M | 1.08M | 1.02M | 1.06M | 1.02M | 0 |
| Retained Earnings | -156.65M | -128.62M | -85.5M | -70.2M | -45.22M | -44.85M | -49.11M | -43.14M | -45.67M | -47.56M | -41.06M | -42.77M | -41.1M | -40.59M | -35.57M | -28.09M | -27.15M | -14.44M | -6.67M | -8.28M | -2.84M | 596.93K | 1.66M | 2.81M | 11.8M | 15.85M | 8.78M | -1.62M | 7.25M | 14.27M |
| Treasury Stock | 0 | -1.02M | -828.4K | -883.72K | -957.32K | -1.06M | -1.14M | -1.04M | -1.31M | -1.37M | -1.2M | -1.14M | -1.17M | -1.17M | -1.17M | -1.17M | -1.17M | -1.23M | -1.3M | -1.3M | -3.02M | -1.79M | -1.8M | -1.79M | -1.8M | -1.8M | -1.73M | -3.11M | -3.07M | 0 |
| Accumulated OCI | 0 | -8.34M | -5.07M | -4.96M | -4.09M | -4.08M | -3.75M | -3.86M | -4.28M | -4.33M | -4.17M | -3.57M | -3.21M | -3.22M | -3.33M | -3.59M | -3.39M | -3.13M | -3.29M | -3.09M | -1.54M | -2.87M | -2.98M | -2.95M | -2.51M | 3.99M | 6.84M | -732.42K | -170.53K | -5M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying FOCL stock.
As of 2025, EDAP TMS S.A. American Depositary Shares (FOCL) had total assets of $79.0M including $57.2M in current assets.
EDAP TMS S.A. American Depositary Shares (FOCL) carries total debt of $27.7M, offset by $20.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
EDAP TMS S.A. American Depositary Shares (FOCL) has total shareholders' equity (book value) of $19.4M ($0.52 book value per share). Book value represents the net worth of the company belonging to common stock holders.
EDAP TMS S.A. American Depositary Shares (FOCL) reported a current ratio of 1.54x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Negative equity amid debt surge and cash depletion
Metrics are mathematically derived from official filings.
Balance Sheet Erosion Accelerates Sharply
EDAP's balance sheet has deteriorated from a net asset position of $53.0M in 2024Q1 to negative equity of -$3.2M by 2026Q2, a swing of over $56M in roughly two years that appears driven by persistent losses and a dramatic increase in borrowing, based on EDAP's reported balance sheets.
Total liabilities rose from $36.1M to $77.8M over the same window while total assets fell from $89.1M to $74.5M, meaning the company is simultaneously accumulating obligations against a shrinking asset base. The cumulative retained earnings deficit of -$152.2M confirms that losses, not one-off charges, are the primary driver. This trajectory, if sustained, raises questions about the company's ability to continue operating as a going concern without external capital.
Debt Surge Signals Strategic or Survival Borrowing
Total debt exploded from $2.3M in 2026Q1 to $41.7M in 2026Q2, an 18-fold sequential increase that has pushed the debt-to-equity ratio to unmeasurable territory given negative equity, representing the single largest structural shift on EDAP's balance sheet in the ten-quarter record.
Prior to this spike, leverage had been modest at $5–9M for most of the period, so the Q2 borrowing appears to be a recent and potentially urgent financing event rather than a gradual strategic levering. With equity now negative, traditional leverage metrics break down, and investors should closely examine the terms, maturities, and covenants attached to this debt. The fact that this borrowing coincided with a quarter of sharply declining revenue and a 56.9% top-line contraction, as noted in the income statement analysis, suggests the financing may have been driven by liquidity necessity rather than opportunistic investment.
Accumulated Deficit Consumes Entire Equity Base
EDAP's equity turned negative at -$3.2M in 2026Q2, with retained earnings at -$152.2M, meaning cumulative losses have not only wiped out the original $53.0M equity base but have created a hole that exceeds reported total assets by a significant margin, as shown in EDAP's balance sheet.
The equity erosion has been relentless: from $53.0M in 2024Q1 through $40.9M in 2024Q4 to $19.4M by 2025Q4, before collapsing to negative territory. No share repurchases or dilutive equity issuances are evident in the data to offset this drawdown. For a medical device company in a competitive peer set where even loss-making peers like Novocure maintain positive equity of $1.6B market cap with 2.90x current ratio, EDAP's equity position appears exceptionally fragile.
Cash Decline and Ratio Compression Raise Near-Term Concerns
Cash fell from $38.4M in 2024Q1 to $11.8M in 2026Q2, a 69% drawdown, while the current ratio compressed from 2.62 to 1.60, suggesting the liquidity buffer that once provided comfortable runway has materially narrowed, according to EDAP's quarterly balance sheets.
The current ratio of 1.60, while still above 1.0, masks the quality of the underlying current assets given that cash represents only $11.8M against $41.7M of total debt, implying the company is increasingly dependent on debt to fund operations rather than internal liquidity. Working capital swings contributed temporary cash relief in recent quarters per the cash flow analysis, but these appear to be one-time inventory or receivable adjustments rather than sustainable sources. At the current burn trajectory of roughly $3–4M per quarter in operating cash outflow, the cash runway appears to be measured in quarters, not years.
Deferred Revenue Collapse Signals Order Pipeline Weakness
Deferred revenue plunged from $7.8M in 2026Q1 to just $923K in 2026Q2, an 88% sequential decline and the lowest level in the ten-quarter record, which may indicate a severe deterioration in contracted but unrecognized revenue and therefore future top-line visibility.
Deferred revenue is a leading indicator for medical device companies, representing committed customer obligations that convert to revenue over time. Its collapse to below $1M, when read alongside the 56.9% revenue decline in the same quarter, paints a consistent picture of demand deterioration that appears unlikely to reverse quickly. The prior stability of this metric in the $5–8M range for multiple quarters makes the Q2 drop appear anomalous and warrants investigation into whether large contracts were cancelled, restructured, or whether there was an accounting reclassification.
Asset Write-Downs Mask Potential Structural Impairment
PPE collapsed from $13.0M to $0 and goodwill fell from $2.8M to $735K between 2026Q1 and 2026Q2, a simultaneous elimination of both tangible and intangible assets that may signal significant impairment charges rather than routine asset disposal, based on EDAP's reported balance sheets.
For a manufacturing medical device company to report zero net PPE is highly unusual and could indicate either a complete write-down of production assets, a classification change, or the sale of manufacturing capability. Combined with the goodwill impairment, these asset reductions appear to contribute to the $15.7M drop in total assets between Q1 and Q2. This pattern warrants careful scrutiny because impairment charges reduce equity without affecting cash flow directly, meaning the headline equity deterioration may be partly non-cash, yet it also implies management no longer sees recoverable value in assets it previously carried.